Acer Inc.

Acer Unveils 3 New Products in the Robust TravelMate Notebook Series for Commercial Use

Retrieved on: 
Wednesday, October 21, 2020
Consumer electronics, Acer TravelMate, Tablet computers, Acer Inc., HP TouchPad, Laptop

The Acer TravelMate Spin P4 and TravelMate P4 notebooks' batteries last up to 15 hours[3], while the while the TravelMate P2 gets up to 13 hours[3]of battery life.

Key Points: 
  • The Acer TravelMate Spin P4 and TravelMate P4 notebooks' batteries last up to 15 hours[3], while the while the TravelMate P2 gets up to 13 hours[3]of battery life.
  • A Precision Touchpad provides intuitive gesture control, while its dockable Acer Active stylus and Windows Ink allow for convenient drawing and note taking.
  • The TravelMate P4 and TravelMate Spin P4 come with a number of quality-of-life updates that ultimately make the transition to working at home easier.
  • Light and highly compact in a semi-metal and versatile design, the powerful TravelMate Spin P4 is just 1.53 kg (3.37 lbs.)

Acer Announces New ConceptD PCs for Creators

Retrieved on: 
Wednesday, October 21, 2020
Classes of computers, Companies, Computing, Computers, Acer Inc., Laptop, Intel, Personal computer

In addition, the ConceptD 7 and ConceptD 7 Pro notebooks now feature 10th Gen Intel Core Processors and Acer's new Vortex Flow cooling technology.

Key Points: 
  • In addition, the ConceptD 7 and ConceptD 7 Pro notebooks now feature 10th Gen Intel Core Processors and Acer's new Vortex Flow cooling technology.
  • Acer's ConceptD PCs elevate the computing experience with their timeless design language, extremely color-accurate displays and silent processing, which distinguish them as something special and out of the ordinary.
  • The newest addition to the ConceptD desktop series, the ConceptD 300 is an elegant and refined mid-sized 18L tower small enough to be unobtrusively placed on a desk.
  • Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners.

Porsche Design and Acer Unveil the Porsche Design Acer Book RS

Retrieved on: 
Wednesday, October 21, 2020
Cars, Car classifications, Motor vehicles, Porsche, Volkswagen Group, Acer Inc., Sports cars

We are delighted to kick-off this partnership with the new Porsche Design Acer Book RS that embodies the DNA of our brand to the core and sets new standards in performance and design," says Jan Becker, CEO of Porsche Design Group

Key Points: 
  • We are delighted to kick-off this partnership with the new Porsche Design Acer Book RS that embodies the DNA of our brand to the core and sets new standards in performance and design," says Jan Becker, CEO of Porsche Design Group
    Jerry Kao, Co-COO of Acer, added: "The fruit of an exciting partnership between Acer and Porsche Design, the Porsche Design Acer Book RS, is a perfect blend of style and performance for urban mobile professionals.
  • Following Porsche Design's design philosophy of optimizing function, the Porsche Design Acer Book RS is a statement in refined computing in which every feature serves a purpose.
  • Compartmentalized and multi-functional by nature, the Porsche Design Acer Travelpack RS (mousepad, mouse, carrying pouch and notebook sleeve) is an ideal companion to accompany[7] the Porsche Design Acer Book RS.
  • The Porsche Design Acer Mouse RS will be available in North America starting at USD 109.99; and in EMEA starting at EUR 99.

Acer Announces Latest Lineup of Consumer Notebooks Across Swift, Spin and Aspire Series

Retrieved on: 
Wednesday, October 21, 2020
Consumer electronics, Companies, Computing, Acer Inc., Intel, Convertible laptops, Ultrabooks, Acer Aspire laptops, Dell Inspiron laptops

TAIPEIOct.21, 2020 /PRNewswire/ -- Acer today introduced a suite of powerful new consumer notebooks across its popular Swift, Spin and Aspire series, all featuring the performance of new 11th Gen Intel Core processors with Intel Iris Xe graphics.

Key Points: 
  • TAIPEIOct.21, 2020 /PRNewswire/ -- Acer today introduced a suite of powerful new consumer notebooks across its popular Swift, Spin and Aspire series, all featuring the performance of new 11th Gen Intel Core processors with Intel Iris Xe graphics.
  • The 2020 Red Dot Design Award-winning Acer Spin 5 is a touchscreen convertible notebook just 1.2 kg[3] light and 14.9 mm thin[3], aimed at those seeking extreme productivity.
  • Like the Spin 5, it also features the latest 11th Gen Intel Core processors with Iris Xe graphics to give professionals and artists solid performance.
  • Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners.

MultiTech Further Expands its Masters Program - Reinforces Commitment to Streamlining IoT Adoption Process for Customers Worldwide

Retrieved on: 
Tuesday, October 13, 2020
Articles, Ambient intelligence, Digital technology, Internet of things, Technology assessment, Technology, Acer Inc., Science and technology

New Masters include:

Key Points: 
  • New Masters include:
    Optimal Design is an innovation and technology firm providing services for connected products.
  • MultiTech Masters provide design, development and integration assistance, as well as project management and other value-added services to MultiTech customers.
  • "The Masters in our program are skilled experts that can help with the design and integration of our devices for specific industries.
  • We expect to eliminate the barriers of implementing IoT solutions, further streamlining the adoption process for our customers."

Acer Reports September Consolidated Revenues of NT$29.51 Billion, Record High in 72 Months

Retrieved on: 
Monday, October 12, 2020
Acer Inc., Yoy, Acer, Maple, Consumer electronics, Companies, Industries

TAIPEI, Oct. 12, 2020 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced today its consolidated revenues for September at NT$29.51 billion, reaching a record high in 72 months[1], and up 21.3% year-on-year (YoY) or 8.2% month-on-month.

Key Points: 
  • TAIPEI, Oct. 12, 2020 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced today its consolidated revenues for September at NT$29.51 billion, reaching a record high in 72 months[1], and up 21.3% year-on-year (YoY) or 8.2% month-on-month.
  • Preliminary consolidated revenues for the third quarter of 2020 reached NT$80.03 billion to set another record in 23 quarters[2], and up 27.3% YoY or 22% quarter-on-quarter.
  • For year-to-September, consolidated revenues were NT$194.49 billion, up 12.6% YoY.
  • Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners.

Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital

Retrieved on: 
Thursday, October 1, 2020
Industries, Companies, Life sciences, Acer Inc., Acer, Medication

NEWTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acers management team will provide a virtual corporate overview at, and participate in, the BIO Investor Forum Digital taking place on October 13-15, 2020.

Key Points: 
  • NEWTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acers management team will provide a virtual corporate overview at, and participate in, the BIO Investor Forum Digital taking place on October 13-15, 2020.
  • The presentation will be available on-demand during the conference.
  • Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.
  • Each of Acers product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.

Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 13, 2020
Acer Inc., eMachines, Food and Drug Administration, Companies, Consumer electronics, Industries

The second quarter of 2020 was marked by significant progress in two of our lead programs emetine and ACER-001, said Chris Schelling, CEO and Founder of Acer.

Key Points: 
  • The second quarter of 2020 was marked by significant progress in two of our lead programs emetine and ACER-001, said Chris Schelling, CEO and Founder of Acer.
  • To that end, we submitted a Type C briefing package to the FDA to discuss these results and are expecting feedback later in the third quarter.
  • We continue to target an ACER-001 NDA filing in the first half of 2021, subject to additional capital.
  • Cash and cash equivalents were $5.9 million as of June 30, 2020, compared to $12.1 million as of December 31, 2019.

Acer Reports Q2 2020 Results: Operating Income NT$2.13 Billion with Record High Margin of 3.2%

Retrieved on: 
Wednesday, August 5, 2020
Acer Inc., Acer, Yoy, Consumer electronics, Companies, Industries

TAIPEI, Aug.5, 2020 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its financial results for the second quarter of 2020: consolidated revenues were NT$65.58 billion; gross profits were NT$7.14 billion with 10.9% margin; operating income was NT$2.13 billion, marking a record high[1] margin of 3.2%; earnings before tax[2] was NT$1.65 billion; and net income[3] was NT$1.20 billion with earnings per share (EPS) of NT$0.40.

Key Points: 
  • TAIPEI, Aug.5, 2020 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its financial results for the second quarter of 2020: consolidated revenues were NT$65.58 billion; gross profits were NT$7.14 billion with 10.9% margin; operating income was NT$2.13 billion, marking a record high[1] margin of 3.2%; earnings before tax[2] was NT$1.65 billion; and net income[3] was NT$1.20 billion with earnings per share (EPS) of NT$0.40.
  • In the six months ended June 30, 2020, Acer's net income reached NT$1.75 billion, up 57.2% year-on-year (YoY) with EPS of NT$0.58.
  • At the same time, Acer's multiple business engines continued their strong momentum; notable performances in Q2 net income include Acer Cyber Security with 24% growth YoY, Weblink International with 25% growth YoY, and Acer Synergy Tech with 88% growth YoY.
  • Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners.

Shareholder Alert: Robbins LLP Announces the Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss

Retrieved on: 
Tuesday, July 28, 2020
Legal, Professional services, Acer Inc., Companies, Acer, Consumer electronics, Industries

Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc. (NASDAQ: ACER) may face damages caused by a pending securities class action.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc. (NASDAQ: ACER) may face damages caused by a pending securities class action.
  • Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for rare and life-threatening diseases.
  • Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss
    According to the complaint, Acer misrepresented that a conversation it had with the U.S. Food and Drug Administration regarding its drug candidate EDVISO.
  • Acer claimed publicly that "the FDA agreed that additional clinical development is not needed" for the drug.